BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Schering-Plough Corporation (SGP) Appoints Susan G. Arbuck, M.D., Vice President, Global Clinical Development, Schering-Plough Research Institute (SGP)


10/19/2005 5:13:06 PM

KENILWORTH, N.J., March 22 /PRNewswire/ -- Schering-Plough Corporation today announced that Susan G. Arbuck, M.D., has been appointed vice president, oncology, global clinical development, for the Schering-Plough Research Institute. She is based in Kenilworth, N.J., and reports to Peder K. Jensen, M.D., executive vice president, global clinical development.

In this role, Arbuck is responsible for the global clinical development of oncology products and represents the global clinical development group on an internal product development committee.

Arbuck recently held the position of vice president and global head of the oncology therapeutic area at Aventis Pharmaceuticals. She is the former head of the Developmental Chemotherapy Section at the National Cancer Institute (NCI). During her career, she contributed to the development and registration of many approved oncology products. She provided leadership in cancer drug development through other efforts, including the development of standardized criteria for adverse event and tumor response reporting, which are used internationally in oncology clinical trials. She also contributed to the development of novel trial designs and strategies to increase the efficiency of cancer drug development and registration.

Arbuck has 10 years experience participating with the FDA in monthly FDA National Cancer Institute working group meetings. She served as a visiting professor at the National Cancer Center in Tokyo, Japan, and has participated in a workshop with The European Agency for the Evaluation of Medicinal Products (EMEA). Arbuck is a board-certified medical oncologist who has served on various committees for the American Association for Cancer Research and American Society of Clinical Oncology. She has more than 100 peer- reviewed publications. She holds a B.Sc. from the University of Toronto, a M.Sc. in Pharmacology from the State University of New York at Buffalo and an M.D. from McMaster University Medical School in Hamilton, Ontario.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/ .

Schering-Plough Corporation

CONTACT: Media: Rosemarie Yancosek, +1-908-298-7476; Investor: JanetBarth, or Alex Kelly, +1-908-298-7436, all of Schering-Plough Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->